| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisNCT03672292 | SCYX | Phase 2 | Terminated | 2023-03-27Actual |
| 9-ING-41 in Patients With Advanced CancersNCT03678883 | ACTU | Phase 2 | Active not recruiting | 2026-06Estimated |
| Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact DermatitisNCT03680131 | EDSA | Phase 2 | Completed | 2022-09-21Actual |
| Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaNCT03687242 | Spruce Biosciences | Phase 2 | Completed | 2019-07-08Actual |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388 | Exelixis | Phase 3 | Active not recruiting | 2020-08-19Actual |
| A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaNCT03692052 | AGIO | Phase 2 | Active not recruiting | 2020-08-20Actual |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeNCT03697109 | Corcept Therapeutics | Phase 3 | Completed | 2024-04-08Actual |
| A Study of OV101 in Individuals With Fragile X SyndromeNCT03697161 | OVID | Phase 2 | Completed | 2020-02-03Actual |
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)NCT03703310 | SLGL | Phase 3 | Completed | 2020-12-28Actual |
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyNCT03719690 | KURA | Phase 2 | Completed | 2023-05-02Actual |
| REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03721978 | Inovio Pharmaceuticals | Phase 3 | Completed | 2022-08-23Actual |
| Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent PericarditisNCT03737110 | Kiniksa Pharmaceuticals (UK), Ltd. | Phase 3 | Completed | 2020-05-29Actual |
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)NCT03745716 | Aprea Therapeutics | Phase 3 | Completed | 2020-11-27Actual |
| Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522 | RYTM | Phase 3 | Completed | 2020-11-16Actual |
| Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791 | Exelixis | Phase 3 | Active not recruiting | 2021-11-30Actual |
| Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisNCT03760003 | ABVX | Phase 2 | Completed | 2021-04-01Actual |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850 | TVTX | Phase 3 | Completed | 2023-08-07Actual |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348 | Replimune, Inc. | Phase 2 | Active not recruiting | 2028-06Estimated |
| Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT03772340 | Vanda Pharmaceuticals | Phase 2 | Completed | 2019-06-06Actual |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812 | Corcept Therapeutics | Phase 2 | Completed | 2021-03-16Actual |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyNCT03796962 | XENE | Phase 2 | Active not recruiting | 2021-09-02Actual |
| Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSNCT03799718 | Brainstorm-Cell Therapeutics | Phase 2 | Completed | 2021-03-11Actual |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525 | TGTX | Phase 2, Phase 3 | Terminated | 2022-12-20Actual |
| GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)NCT03815825 | IONS | Phase 2 | Completed | 2024-04-18Actual |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsNCT03818256 | Corcept Therapeutics | Phase 2 | Completed | 2022-06-17Actual |
| KPL-301 for Subjects With Giant Cell ArteritisNCT03827018 | Kiniksa Pharmaceuticals, Ltd. | Phase 2 | Completed | 2020-08-13Actual |
| Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaNCT03828448 | TGTX | Phase 2 | Terminated | 2022-05-16Actual |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyNCT03829449 | AKARI Therapeutics | Phase 3 | Terminated | 2020-08-29Actual |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03834753 | OTLK | Phase 3 | Completed | 2021-06-07Actual |
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSDNCT03841773 | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 2020-04-24Actual |
Trial details
- Registry ID
- NCT03672292
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03678883
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03680131
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03687242
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03690388
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03692052
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03697109
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03697161
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03703310
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03719690
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03721978
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03737110
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03745716
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03746522
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03755791
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03760003
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03762850
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03767348
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03772340
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03776812
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03796962
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03799718
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03801525
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03815825
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03818256
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03827018
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03828448
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03829449
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03834753
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03841773
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.